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Abstract
Anti-SSA/Ro antibodies are necessary but not sufficient to provoke autoimmune-associated
congenital heart block (CHB). Genetic factors are likely contributory. Accordingly, HLA-related
candidates and single-nucleotide polymorphisms in the promoter region of tumor necrosis factor α
and codon 10 in transforming growth factor β1 (TGFβ1) were evaluated in a unique family: the
surrogate mother (anti-SSA/Ro positive), the biologic father, and the CHB-affected child (product
of ovodonation). There was an HLA mismatch between the affected child and the surrogate
mother. However, both the biologic and the surrogate mothers shared DQ2 and the profibrosing
leucine polymorphism at codon 10 of TGFβ. In conclusion, we observed that CHB can develop in
a genetically unrelated child exposed in utero to anti-SSA/Ro antibodies. Testing for anti-SSA/Ro
antibodies might be considered in women undergoing artificial fertilization. It is possible that
there is no direct association of maternal genes beyond a contributory role in generating the
autoantibody.
Autoimmune-associated congenital heart block (CHB) is the clinical end point following a
pathologic cascade of immunologic/fibrotic events that occur in 2% of fetuses exposed to
maternal anti-SSA/Ro and/or anti-SSB/La antibodies (1). Accumulating evidence supports
the necessity of maternal autoantibodies for the development of CHB (for review, see ref. 2).
However, the low penetrance of disease suggests that other factors, such as maternal and
fetal genetics, may be contributory. It is well established that the maternal genes HLA–
DRB1*02 and *03 are strongly associated with the presence of SSA/Ro and SSB/La
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antibodies, regardless of whether the mother has Sjögren’s syndrome, has systemic lupus
erythematosus, or is asymptomatic (3,4).
Susceptibility genes may involve a broad spectrum of candidates ranging from effector
pathways involving antigen presentation (e.g., HLA) to effector pathways controlling both
cellular inflammation and fibrosis. Previous studies have demonstrated that the A
polymorphism at the −308 promoter (tumor necrosis factor 2 [TNF2]) of the TNFα gene and
the leucine polymorphism at codon 10 of the transforming growth factor β (TGFβ) gene
(possibly conferring increased inflammation and scarring potential, respectively) occur more
frequently in children with CHB than in their unaffected siblings (5). With regard to HLA,
Siren et al reported an increased frequency of class I HLA–Cw3 in children with CHB
compared with their mothers and healthy subjects from the general population (6). The HLA
alleles that were enriched in the mothers were DRB1*03, DQB1*02, DQA1*05, and HLA–
Cw7 (7), a finding corroborated by Colombo and colleagues (8). The available data suggest
that genetic effects at the HLA complex may be operating at both maternal and fetal levels.
The current study was initiated to identify whether genes of the HLA complex and other
candidate genes, of maternal or fetal origin, are associated with clinical disease in the fetus,
or whether solely HLA alleles predispose to autoantibody secretion, a required but not
sufficient factor for disease development. The availability of a unique family in which CHB
developed in a fetus conceived by in vitro fertilization of a donor egg that was implanted in
an unrelated woman with anti-SSA/Ro antibodies provided insight into these issues.
CASE REPORT
The surrogate mother (patient), a 36-year-old asymptomatic Italian white woman, underwent
ovodonation due to infertility (gravida 0). The biologic mother was healthy and without any
known autoimmune disease. The oocyte was fertilized by the surrogate mother’s husband
(the biologic father). Following successful implantation, the surrogate mother received folic
acid and progestins for 3 months.
Assessments during the pregnancy included normal results of obstetric ultrasonography at
weeks 8, 10, and 16. At 23 weeks, an echocardiogram revealed complete atrioventricular
block in the fetus, with a ventricular rate of 52 beats per minute and an atrial rate of 130–140
beats per minute. The fetus showed no signs of an associated cardiomyopathy, and
ventricular function was normal. However, mild left ventricle dilatation and tricuspid
regurgitation were noted. There were no anatomic abnormalities.
The surrogate mother was subsequently evaluated and found to have antinuclear antibodies
(1:640 titer) and antibodies reactive with SSA/Ro and SSB/La. Tests for anti–double-
stranded DNA antibodies, rheumatoid factor, and antithyroid antibodies all had negative
results. An extensive rheumatologic evaluation revealed only a history of photosensitivity.
The surrogate mother was treated with dexamethasone (4 mg intramuscularly, twice daily at
24 weeks), and salbutamol (12 mg daily). The dosage of dexamethasone was then reduced at
25 weeks to 4 mg orally daily, and treatment was continued throughout the remainder of the
pregnancy. However, there was no effect on the fetal ventricular rate.
At 37 weeks, a male child (2,810 gm) was delivered by caesarean section. Two days after
his birth, a pacemaker was inserted in the child, whose ventricular rate was 50 beats per
minute. Dexamethasone was discontinued and replaced by tapering doses of prednisone. The
child was breastfed. In the months after birth, clinical and echocardiographic signs of severe
dilated cardiomyopathy developed in the child. Given the severity of disease, the child
received a heart transplant at the age of 17 months.
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Results of the analysis of candidate genes in the family members are shown in Table 1. The
child with CHB had HLA–DQB1*0206, DRB1*0713, and Cw*0416, and the biologic father
had DQB1*0306, DRB1*0413, and Cw*0416. Based on the genetic evaluation of the
biologic father and the child with CHB, the biologic mother shared DQB1*02. The child
carried the TGFβ polymorphism at Leu10 (also conferred by the egg donor) but did not have
the TNFα −308A polymorphism, the TNF2 allele.
DISCUSSION
The rarity of CHB suggests that its pathogenesis represents a complex interplay between
immunologic, genetic, and environmental factors. The necessity for fetal exposure to
maternal autoantibodies reactive with SSA/Ro is strongly supported by this unique case in
which isolated heart block developed in the implanted conceptus of an unrelated egg donor.
Maternal genes may promote cardiac disease via 2 mechanisms, maternal and fetal. Such
promotion by maternal means suggests that these genes would be expected to facilitate
generation of the requisite autoantibodies. Support for this possibility is the presence of DR3
in the surrogate mother (7,8). Fetal inheritance of maternal genes that confer some
permissive factor in the cascade to cardiac scarring cannot be unambiguously assigned in
this situation, because both DQ2 as well as the profibrosing TGFβ allele were shared
between the surrogate and biologic mothers. Furthermore, the contribution of placental
genes per se (i.e., maternal decidua basalis) is also confounded by this sharing. Moreover, it
is notable that HLA and the candidate polymorphisms in TGFβ and TNFα that are
overrepresented in the biologic mothers of children with CHB (7,9,10) were present in the
surrogate mother. This finding may simply represent the common genes associated with
generation of the putative antibodies described above, but it is nevertheless provocative. As
in other polygenetic disorders, associated alleles may be common in the population, and thus
the ovum donor may have to carry these susceptibility alleles. These alleles may be
important in conferring host fetal injury induced by maternal anti-SSA/Ro antibodies.
Further studies are needed to evaluate the maternal genetic risk factors that could influence
the placenta and subsequently the fetal environment. In addition, paternal factors may confer
protection.
Testing for anti-Ro/SSA antibodies might be considered in women undergoing artificial
fertilization. Despite the rarity of CHB, even in mothers with these autoantibodies,
knowledge based on the results of such testing might be helpful for women contemplating
undergoing artificial fertilization in order to weigh the risks and benefits. Although it is
unknown from this case report whether maternal genes per se contribute to a fetal genetic
susceptibility component, maternal genes do appear to contribute to the required
autoantibody response.
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